^
    Back
    Association details:
    Biomarker:CTAG1B expression
    Cancer:Synovial Sarcoma
    Drug:mipetresgene autoleucel (TBI-1301) (TCR modulator, NY ESO 1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

    Excerpt:
    ...- Tumor NY-ESO-1 expression by immunohistochemistry....
    Trial ID:
    NCT02869217
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients With Synovial Sarcoma

    Excerpt:
    ...Tumor that express NY-ESO-1 by immunohistochemistry 6....
    Trial ID:
    NCT03250325
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Safety and Efficacy of NY-ESO-1 Antigen-specific T-cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial

    Published date:
    10/04/2023
    Excerpt:
    Eligible Japanese patients (HLA-A*02:01 or *02:06, NY-ESO-1-positive tumor expression) received cyclophosphamide 750 mg/m2 on days -3 and -2 (induction period) followed by a single dose of 5 x 109 (±30%) TBI-1301 cells as a divided infusion on days 0 and 1 (treatment period)....Adoptive immunotherapy with TBI-1301 to selectively target NY-ESO-1 positive tumor cells appears to be a promising strategy for the treatment of advanced or recurrent synovial sarcoma with acceptable toxicity.
    Secondary therapy:
    cyclophosphamide
    DOI:
    10.1158/1078-0432.CCR-23-1456